Mark Fishman Net Worth

Mark Fishman biography

Dr. Mark C. Fishman M.D. serves as Independent Director of the Company. Dr. Fishman is a Professor in the Harvard Department of Stem Cell and Regenerative Biology and Chief of the Pathways Clinical Service at Massachusetts General Hospital. In February 2019, he became a Co-Founding Partner of Aditum Bio Fund and Chairman of its Scientific and Medical Advisory Board. From 2002 through 2016, Dr. Fishman was the founding President of the Novartis Institutes for BioMedical Research (NIBR), a member of the Executive Committee of Novartis, AG, and served on the Board of Directors of Novartis International Pharmaceutical LTD and Chaired the Board of Directors of the Genomics Institute of the Novartis Research Foundation. Prior to his time at NIBR, he was the Founding Director of the Cardiovascular Research Center and Chief of Cardiology at Massachusetts General Hospital. Dr. Fishman also has served as the Chairman of the Board of privately held Semma Therapeutics since 2016. He also serves as a consultant to and Scientific Advisory Board member of several other privately held biotechnology companies. Dr. Fishman graduated from Yale College and Harvard Medical School and trained in medicine and cardiology at Massachusetts General Hospital. Fishman’s experience studying genetics and regenerative medicine makes him qualified to serve on our Board of Directors.

What is the salary of Mark Fishman?

As the Independent Director of Beam Therapeutics, the total compensation of Mark Fishman at Beam Therapeutics is $50,000. There are 7 executives at Beam Therapeutics getting paid more, with Terry-Ann Burrell having the highest compensation of $4,302,720.

How old is Mark Fishman?

Mark Fishman is 68, he's been the Independent Director of Beam Therapeutics since 2018. There are no older and 16 younger executives at Beam Therapeutics.

What's Mark Fishman's mailing address?

Mark's mailing address filed with the SEC is C/O BEAM THERAPEUTICS INC., 238 MAIN STREET, CAMBRIDGE, MA, 02142.

Insiders trading at Beam Therapeutics

Over the last 5 years, insiders at Beam Therapeutics have traded over $63,012,019 worth of Beam Therapeutics stock. The most active insiders traders include Group, Llc Green Jeremy Red..., Llc Fmr a Kristina Burow. On average, Beam Therapeutics executives and independent directors trade stock every 26 days with the average trade being worth of $1,019,987. The most recent stock trade was executed by Amy Simon on 1 July 2024, trading 1,250 units of BEAM stock currently worth $29,100.

What does Beam Therapeutics do?

Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia. It also develops therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1a; and therapies for ocular and central nervous system disorders. The company has a strategic alliance with Boston Children's Hospital; a research and clinical collaboration agreement with Magenta Therapeutics, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration with Apellis Pharmaceuticals, Inc. to apply base editing technology for discovering new treatments for complement-driven diseases. Beam Therapeutics Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

Beam Therapeutics executives and stock owners

Beam Therapeutics executives and other stock owners filed with the SEC include:

• Terry-Ann Burrell,
  Chief Financial Officer, Treasurer
• John Evans,
  Chief Executive Officer, Director
• Giuseppe Ciaramella,
  President, Chief Scientific Officer
• John M. Evans M.B.A.,
  CEO & Director
• Dr. Giuseppe Ciaramella Ph.D.,
  Pres & Chief Scientific Officer
• Terry-Ann Burrell M.B.A.,
  CFO & Treasurer
• Carole Ho,
  Independent Director
• Mark Fishman,
  Independent Director
• Graham Cooper,
  Independent Director
• Robert Nelsen,
  Independent Director
• Stephen Knight,
  Independent Director
• Kristina Burow,
  Independent Director
• Christine Swenson,
  Senior Vice President - Regulatory Affairs
• Manmohan Singh,
  Senior Vice President - Pharmaceutical Sciences and Delivery Technology
• David Liu,
  Co-Founder
• J. Keith Joung,
  Co-Founder
• Dr. Alexis Komor Ph.D.,
  Co-Founder
• Dr. Nicole Gaudelli Ph.D.,
  Co-Founder
• Suzanne Fleming,
  Chief Accounting Officer
• Dr. J. Keith Joung M.D., Ph.D.,
  Co-Founder
• Courtney Wallace,
  Chief Bus. Officer
• Susan O'Connor,
  Chief HR Officer
• Dr. Christine P. Bellon J.D., Ph.D.,
  Sr. VP, Chief Legal Officer & Corp. Sec.
• Brian Riley,
  Sr. VP of Technical Operations
• Dr. Feng Zhang,
  Co-Founder
• John Maraganore,
  
• Kathleen E Walsh,
  
• Bethany J Cavanagh,
  SVP, Finance and Treasurer
• Group, Llc Green Jeremy Red...,
  
• Venture Partners Ix, Llcarc...,
  
• Venture Partners Ix, Llcarc...,
  
• Llc Fmr,
  
• Amy Simon,
  Chief Medical Officer
• Christine Bellon,
  Chief Legal Officer
• Christi Shaw,